These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1728 related articles for article (PubMed ID: 30153823)
41. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer. Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188 [TBL] [Abstract][Full Text] [Related]
42. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis. Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614 [No Abstract] [Full Text] [Related]
43. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370 [TBL] [Abstract][Full Text] [Related]
44. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients. Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065 [TBL] [Abstract][Full Text] [Related]
45. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850 [TBL] [Abstract][Full Text] [Related]
46. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624 [TBL] [Abstract][Full Text] [Related]
47. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547 [TBL] [Abstract][Full Text] [Related]
48. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582 [TBL] [Abstract][Full Text] [Related]
49. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing. Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147 [TBL] [Abstract][Full Text] [Related]
50. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future. Scilla KA; Rolfo C Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467 [TBL] [Abstract][Full Text] [Related]
51. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773 [TBL] [Abstract][Full Text] [Related]
52. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. Esagian SM; Grigoriadou GΙ; Nikas IP; Boikou V; Sadow PM; Won JK; Economopoulos KP J Cancer Res Clin Oncol; 2020 Aug; 146(8):2051-2066. PubMed ID: 32462295 [TBL] [Abstract][Full Text] [Related]
53. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Ma C; Yang X; Xing W; Yu H; Si T; Guo Z Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608 [TBL] [Abstract][Full Text] [Related]
54. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia. Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856 [TBL] [Abstract][Full Text] [Related]
55. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713 [TBL] [Abstract][Full Text] [Related]
56. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Shields MD; Chen K; Dutcher G; Patel I; Pellini B Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272 [TBL] [Abstract][Full Text] [Related]
57. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing. He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796 [TBL] [Abstract][Full Text] [Related]
58. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733 [TBL] [Abstract][Full Text] [Related]
59. Single tube liquid biopsy for advanced non-small cell lung cancer. de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653 [TBL] [Abstract][Full Text] [Related]
60. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]